Gregg Anthony Lapointe's most recent trade in Soligenix Inc was a trade of 8,646 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 12, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Soligenix Inc | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2024 | 8,646 | 8,646 | - | - | Stock Option (Right to Buy) | |
Astria Therapeutics Inc | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
Rigel Pharmaceuticals | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
Rigel Pharmaceuticals | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2024 | 25,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
Soligenix Inc | Anthony Lapointe Gregg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2023 | 38,136 | 38,136 | - | - | Stock Option (Right to Buy) | |
Astria Therapeutics Inc | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
Rigel Pharmaceuticals | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
Rigel Pharmaceuticals | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 25,000 | 75,000 (0%) | 0% | 0 | Common Stock | |
Soligenix Inc | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2022 | 46,154 | 129,747 | - | - | Stock Option (Right to Buy) | |
Astria Therapeutics Inc | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,333 | 8,333 | - | - | Stock Option (right to buy) | |
Rigel Pharmaceuticals | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
Rigel Pharmaceuticals | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 25,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
Soligenix Inc | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2021 | 29,126 | 29,126 | - | - | Stock Option (Right to Buy) | |
Astria Therapeutics Inc | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
Soligenix Inc | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2020 | 15,228 | 15,228 | - | - | Stock Option (Right to Buy) | |
Astria Therapeutics Inc | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) |